A new trading day began on Thursday, with Verve Therapeutics Inc (NASDAQ: VERV) stock price up 1.77% from the previous day of trading, before settling in for the closing price of $4.51. VERV’s price has ranged from $2.86 to $9.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 136.15% over the last five years. Meanwhile, its annual earnings per share averaged -13.06%. With a float of $66.12 million, this company’s outstanding shares have now reached $88.76 million.
The firm has a total of 274 workers. Let’s measure their productivity. In terms of profitability, gross margin is 84.37%, operating margin of -707.23%, and the pretax margin is -613.51%.
Verve Therapeutics Inc (VERV) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Verve Therapeutics Inc is 25.54%, while institutional ownership is 69.99%. The most recent insider transaction that took place on Apr 02 ’25, was worth 40,761. In this transaction Chief Executive Officer of this company sold 9,822 shares at a rate of $4.15, taking the stock ownership to the 346,686 shares. Before that another transaction happened on Apr 02 ’25, when Company’s Chief Administrative Officer sold 2,777 for $4.15, making the entire transaction worth $11,525. This insider now owns 17,420 shares in total.
Verve Therapeutics Inc (VERV) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.67 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -13.06% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.26% during the next five years compared to -42.43% drop over the previous five years of trading.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Here are Verve Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 12.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.35, a number that is poised to hit -0.64 in the next quarter and is forecasted to reach -2.66 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Analysing the last 5-days average volume posted by the [Verve Therapeutics Inc, VERV], we can find that recorded value of 13.7 million was better than the volume posted last year of 2.41 million. As of the previous 9 days, the stock’s Stochastic %D was 62.03%. Additionally, its Average True Range was 0.62.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 26.84%, which indicates a significant decrease from 58.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 184.61% in the past 14 days, which was higher than the 115.19% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.89, while its 200-day Moving Average is $5.90. Now, the first resistance to watch is $4.81. This is followed by the second major resistance level at $5.03. The third major resistance level sits at $5.22. If the price goes on to break the first support level at $4.40, it is likely to go to the next support level at $4.21. Should the price break the second support level, the third support level stands at $3.99.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
With a market capitalization of 407.57 million, the company has a total of 88,796K Shares Outstanding. Currently, annual sales are 32,330 K while annual income is -198,710 K. The company’s previous quarter sales were 13,080 K while its latest quarter income was -50,040 K.
